Joshua P Entrop1, Susanna Kullberg2,3, Johan Grunewald2,3, Anders Eklund2,3, Kerstin Brismar4, Elizabeth V Arkema1. 1. Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 2. Division of Respiratory Medicine, Dept of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 3. Theme Inflammation and Infection, Dept of Respiratory Medicine, Karolinska University Hospital, Stockholm, Sweden. 4. Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: The rate of type 2 diabetes mellitus (T2D) is increased in sarcoidosis patients but it is unknown if corticosteroid treatment plays a role. We investigated whether the T2D risk is higher in untreated and corticosteroid-treated sarcoidosis patients compared with the general population. METHODS: In this cohort study, individuals with two or more International Statistical Classification of Diseases and Related Health Problems (ICD) codes for sarcoidosis were identified from the Swedish National Patient Register (NPR) (n=5754). Corticosteroid dispensations within 3 months before or after the first sarcoidosis diagnosis were identified from the Swedish Prescribed Drug Register (PDR). General population comparators without sarcoidosis were matched to cases 10:1 on age, sex and region of residence (n=61 297). Incident T2D was identified using ICD codes (NPR) and antidiabetic drug dispensations (PDR). Follow-up was from the second sarcoidosis diagnosis/matching date until T2D, emigration, death or study end (December 2013). Cox regression models adjusted for age, sex, education, country of birth, healthcare regions and family history of diabetes were used to estimate hazard ratios (HRs). We used flexible parametric models to examine the T2D risk over time. RESULTS: 40% of sarcoidosis patients were treated with corticosteroid at diagnosis. The T2D rate was 7.7 per 1000 person-years in untreated sarcoidosis, 12.7 per 1000 person-years in corticosteroid-treated sarcoidosis and 5.5 per 1000 person-years in comparators. The HR for T2D was 1.4 (95% CI 1.2-1.8) associated with untreated sarcoidosis and 2.3 (95% CI 2.0-3.0) associated with corticosteroid-treated sarcoidosis. The T2D risk was highest for corticosteroid-treated sarcoidosis in the first 2 years after diagnosis. CONCLUSIONS: Sarcoidosis is associated with an increased risk of T2D especially in older, male, corticosteroid-treated patients at diagnosis. Screening for T2D for these patients is advisable.
BACKGROUND: The rate of type 2 diabetes mellitus (T2D) is increased in sarcoidosis patients but it is unknown if corticosteroid treatment plays a role. We investigated whether the T2D risk is higher in untreated and corticosteroid-treated sarcoidosis patients compared with the general population. METHODS: In this cohort study, individuals with two or more International Statistical Classification of Diseases and Related Health Problems (ICD) codes for sarcoidosis were identified from the Swedish National Patient Register (NPR) (n=5754). Corticosteroid dispensations within 3 months before or after the first sarcoidosis diagnosis were identified from the Swedish Prescribed Drug Register (PDR). General population comparators without sarcoidosis were matched to cases 10:1 on age, sex and region of residence (n=61 297). Incident T2D was identified using ICD codes (NPR) and antidiabetic drug dispensations (PDR). Follow-up was from the second sarcoidosis diagnosis/matching date until T2D, emigration, death or study end (December 2013). Cox regression models adjusted for age, sex, education, country of birth, healthcare regions and family history of diabetes were used to estimate hazard ratios (HRs). We used flexible parametric models to examine the T2D risk over time. RESULTS: 40% of sarcoidosis patients were treated with corticosteroid at diagnosis. The T2D rate was 7.7 per 1000 person-years in untreated sarcoidosis, 12.7 per 1000 person-years in corticosteroid-treated sarcoidosis and 5.5 per 1000 person-years in comparators. The HR for T2D was 1.4 (95% CI 1.2-1.8) associated with untreated sarcoidosis and 2.3 (95% CI 2.0-3.0) associated with corticosteroid-treated sarcoidosis. The T2D risk was highest for corticosteroid-treated sarcoidosis in the first 2 years after diagnosis. CONCLUSIONS: Sarcoidosis is associated with an increased risk of T2D especially in older, male, corticosteroid-treated patients at diagnosis. Screening for T2D for these patients is advisable.
Authors: Cecilia Carlens; Maria-Pia Hergens; Johan Grunewald; Anders Ekbom; Anders Eklund; Caroline Olgart Höglund; Johan Askling Journal: Am J Respir Crit Care Med Date: 2010-03-04 Impact factor: 21.405
Authors: Elizabeth V Arkema; Johan Grunewald; Susanna Kullberg; Anders Eklund; Johan Askling Journal: Eur Respir J Date: 2016-07-28 Impact factor: 16.671
Authors: Nauman A Khan; Christopher V Donatelli; Adriano R Tonelli; Jonathan Wiesen; Manuel L Ribeiro Neto; Debasis Sahoo; Daniel A Culver Journal: Respir Med Date: 2017-09-08 Impact factor: 3.415
Authors: Marios Rossides; Susanna Kullberg; Anders Eklund; Johan Grunewald; Elizabeth V Arkema Journal: Respir Med Date: 2019-11-26 Impact factor: 3.415
Authors: Orianne Dumas; Krislyn M Boggs; Yvette C Cozier; Meir J Stampfer; Carlos A Camargo Journal: Eur Respir J Date: 2017-10-19 Impact factor: 16.671
Authors: Marios Rossides; Susanna Kullberg; Johan Grunewald; Anders Eklund; Daniela Di Giuseppe; Johan Askling; Elizabeth V Arkema Journal: Heart Date: 2021-05-21 Impact factor: 5.994